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Summary
Background People who inject drugs (PWID) experience a high prevalence of incarceration and might be at high risk 
of HIV and hepatitis C virus (HCV) infection during or after incarceration. We aimed to assess whether incarceration 
history elevates HIV or HCV acquisition risk among PWID.
Methods In this systematic review and meta-analysis, we searched MEDLINE, Embase, and PsycINFO databases for 
studies in any language published from Jan 1, 2000 until June 13, 2017 assessing HIV or HCV incidence among 
PWID. We included studies that measured HIV or HCV incidence among community-recruited PWID. We included 
only studies reporting original results and excluded studies that evaluated incident infections by self-report. We 
contacted authors of cohort studies that met the inclusion or exclusion criteria, but that did not report on the outcomes 
of interest, to request data. We extracted and pooled data from the included studies using random-effects meta-analyses 
to quantify the associations between recent (past 3, 6, or 12 months or since last follow-up) or past  incarceration and 
HIV or HCV acquisition (primary infection or reinfection) risk among PWID. We assessed the risk of bias of included 
studies using the Newcastle-Ottawa Scale. Between-study heterogeneity was evaluated using the I² statistic and the 
P-value for heterogeneity.
Findings We included published results from 20 studies and unpublished results from 21 studies. These studies 
originated from Australasia, western and eastern Europe, North and Latin America, and east and southeast Asia. 
Recent incarceration was associated with an 81% (relative risk [RR] 1∙81, 95% CI 1∙40–2∙34) increase in HIV 
acquisition risk, with moderate heterogeneity between studies (I²=63∙5%; p=0∙001), and a 62% (RR 1∙62, 95% CI 
1∙28–2∙05) increase in HCV acquisition risk, also with moderate heterogeneity between studies (I²=57∙3%; p=0∙002). 
Past incarceration was associated with a 25% increase in HIV (RR 1∙25, 95% CI 0∙94–1∙65) and a 21% increase in 
HCV (1∙21, 1∙02–1∙43) acquisition risk.
Interpretation Incarceration is associated with substantial short-term increases in HIV and HCV acquisition risk 
among PWID and could be a significant driver of HCV and HIV transmission among PWID. These findings support 
the need for developing novel interventions to minimise the risk of HCV and HIV acquisition, including addressing 
structural risks associated with drug laws and excessive incarceration of PWID.
Funding Engineering and Physical Sciences Research Council, National Institute for Health Research, National 
Institutes of Health.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Hepatitis C virus (HCV) and HIV are leading causes of 
morbidity and mortality and continue to represent major 
global public health concerns.1,2 Injecting drug use is 
associated with two-fifths of the global HCV disease 
burden,3 while outside sub-Saharan Africa, an estimated 
one-fifth of new HIV infections occur among people who 
inject drugs (PWID).4
PWID have a high prevalence of incarceration 
(58% have ever been incarcerated5), with a history of 
incarceration frequently being associated with prevalent 
HIV and HCV infection.6 The risk of relapse to illicit 
drug use is high in the period immediately following 
release from prison,7,8 and so individuals are at an 
increased risk of multiple adverse outcomes during this 
period—in particular drug-related deaths,9 but also 
increased injecting risk behaviours and homelessness,10–13 
and reduced access to interventions such as opioid 
substitution therapy and HIV antiretroviral therapy.12,14
Several recent modelling analyses have suggested 
that incarceration of PWID could be an important 
contributor to HIV and HCV transmission among 
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PWID, largely owing to the high prevalence of 
incarceration among this group and an elevated 
transmission risk following release.11,15–17 Furthermore, 
these studies suggest that the period following release 
could be a key prevention target for reducing the trans-
mission of HIV and HCV among PWID. However, the 
magnitude and mechanism of this elevated risk follow-
ing incarceration is not well understood, and there is 
scarce empirical evidence to support existing modelling, 
inform policy change, or aid in the development of 
interventions that target this period of risk.
To improve the evidence base, we did a systematic 
review and meta-analysis to quantify the association 
between incarceration history, either past or recent, and 
HIV or HCV acquisition risk among PWID.
Methods
Search strategy and selection criteria
We did searches of MEDLINE, Embase, and PsycINFO 
databases without language restrictions. Search terms 
included those related to HIV infection or transmission, 
HCV infection or transmission, injecting drug use, and 
study designs that could be used to evaluate HIV or 
HCV incidence (a full list of search terms is provided in 
the appendix). We initially searched up to June 6, 2016, 
but subsequently up dated our search to include studies 
published up to June 13, 2017. Studies, including those 
from conference abstracts, were limited to those 
published since 2000. Reference lists of syste matic 
reviews were hand-searched for additional relevant 
papers or reports.
Research in context
Evidence before the study
We searched PubMed up to Jan 17, 2018, for “HIV OR hepatitis C 
OR HCV” AND “incarceration” AND “inject drugs, injecting drug, 
substance abuse, intravenous/epidemiology [MeSH]” OR 
“substance-related disorders/epidemiology [MeSH]”, with no 
restrictions on language or date. The findings of identified 
studies suggest that previous incarceration is negatively 
associated with injecting cessation (two studies) and being on 
opioid substitution therapy (three studies), but is positively 
associated with prevalent HIV and hepatitis C virus (HCV) 
infection (17 studies), police harassment (one study), relapse to 
injecting drug use (one study), unstable housing or 
homelessness (three studies), overdose (four studies), mortality 
(one study), and several high-risk, drug-using behaviours such 
as receptive syringe sharing, public injecting, and cocaine 
injecting (16 studies). We identified a systematic review on the 
associations between criminalisation of drug use and HIV 
prevention and treatment-related outcomes among people 
who inject drugs (PWID), which included only one study 
measuring the association between incarceration history and 
HIV acquisition risk among PWID. In addition to the study 
identified in that review, our search found five further studies 
presenting the association between incarceration (either recent 
or past) and HIV acquisition risk, as well as three studies 
presenting the association between incarceration (either recent 
or past) and HCV acquisition risk; all of these studies were also 
identified in our systematic review. The search also identified 
three mathematical modelling studies (two done by our team) 
that suggest that incarceration could substantially contribute 
to HIV and HCV transmission among PWID, and that scaling up 
prison-based opioid substitution therapy with retention 
following release could be an effective prevention strategy.
Added value of this study
To our knowledge, this is the first systematic review and 
meta-analysis of the effect of incarceration on HIV or HCV 
acquisition risk among community-based PWID. Our study also 
builds on previously published evidence through collating and 
synthesising unpublished estimates by contacting authors of all 
identified studies of PWID that have a measure of HIV or HCV 
incidence. This approach resulted in 28 additional estimates 
being included in our meta-analysis, doubling the overall 
number of studies. We found that recent (past 3, 6, or 
12 months or since last follow-up) incarceration was associated 
with an increased risk of both HIV and HCV acquisition among 
community-based PWID. These associations persisted when 
only adjusted estimates were pooled, as well as in numerous 
sensitivity analyses. Past incarceration was only weakly 
associated with elevated HIV or HCV acquisition risk, with there 
being no association when only adjusted estimates are pooled. 
The association between recent incarceration and HCV 
acquisition risk was greater in studies with higher prevalences 
of homelessness and in countries with higher prevalences of 
incarceration and reduced in studies adjusting for 
homelessness.
Implications of all the available evidence
Evidence suggests that incarceration is an important enhancer 
of HIV and HCV acquisition risk among PWID globally and 
probably a significant driver of HIV and HCV transmission 
among PWID in many settings because of the high prevalence 
of incarceration among this group. Research is now required to 
better understand how incarceration elevates HIV and HCV 
acquisition risk. This research will be useful for guiding the 
development of interventions to mitigate this risk, with our 
findings suggesting that interventions are needed to address 
the social vulnerabilities experienced by PWID when they are 
released from prison. Our study strengthens the evidence of 
the harms caused by the criminalisation of drug users, which 
results in a high prevalence of incarceration among people 
who use drugs, and provides further evidence to support 
minimising the use of criminal sanctions to manage drug-use 
disorders. 
Articles
www.thelancet.com/infection   Vol 18   December 2018 1399
(Prof S J Hutchinson, 
N E Palmateer); Faculty of 
Public Health and Policy, 
London School of Hygiene and 
Tropical Medicine, London, UK 
(L Platt PhD); and Yale School of 
Medicine, Department of 
Medicine, Section of Infectious 
Diseases, AIDS Program, 
New Haven, CT, USA 
(Prof F L Altice MD)
Correspondence to: 
Dr Jack Stone, Population Health 
Sciences, Bristol Medical School, 
University of Bristol, Bristol BS8 
2BN, UK 
jack.stone@bristol.ac.uk
See Online for appendix
An Endnote library was created to catalogue the search 
results, with removal of duplicates. Titles and abstracts 
were screened for potential relevance, with full texts 
obtained and further screened for those deemed relevant. 
This screening was done by one author (JS), with a subset 
of references (10%) also screened by other authors 
(SA, HF, AGL, LMac, AT, JGW, and ZW). No discrepancies 
were found between the two lists of accepted references 
and so no further double screening was done. We read 
non-English full text papers using Google Translate.
The key outcomes of interest were the association 
between recent (past 3, 6, or 12 months or since last follow-
up) or past incarceration and HIV or HCV incidence 
(either primary infection or reinfection) among PWID—
that is, the difference in the risk of acquiring HIV or HCV 
infection among recently incarcerated PWID compared 
with PWID without recent incarceration, or among PWID 
who have previously been incarcerated compared with 
PWID who have never been incarcerated. Throughout this 
paper, we use the term incarceration to refer to the detention 
of people in prisons, jails (in the US and other settings, 
jails are typically used for short-term detention, either for 
those awaiting trial or with short sentences, whereas 
prisons are used to detain those with longer sentences), or 
other closed settings and use the term prison to refer to 
any such setting where someone might be detained.
We included studies that measured HIV or HCV 
incidence among community-recruited samples of 
PWID, either current or former injectors. We included 
studies that measured incidence by repeated testing 
or that used biological markers of recent HIV or HCV 
infection to estimate incidence. Studies that evaluated 
incident infections by self-report were excluded, as were 
studies that recruited participants directly from prisons 
or other detention settings. We did not exclude studies 
on the basis of study design or language, but included 
only studies reporting original results. We contacted 
authors of cohort studies that met the inclusion or ex-
clusion criteria, but that did not report on the out-
comes of interest, to request data. This approach followed 
methods used in previous systematic reviews on HIV 
and HCV.18,19 Studies that presented data or provided 
unpublished data on the outcomes of interest were 
included. When there were multiple studies from the 
same cohort of PWID with estimates of the same 
outcome, only the most comprehensive study, in terms 
of the number of participants and years covered, was 
included. Methods of the analysis and inclusion criteria 
were specified in advance and documented in a protocol 
available on request.
Data analysis
JS extracted data (list of data extracted in appendix) from 
included studies using Microsoft Excel 2016 for Mac; 
these were checked by HF, and discrepancies were 
resolved by PV. If not reported, effects and 95% CIs were 
calculated from raw data. We extracted or generated 
crude and adjusted incidence rate ratios and hazard 
ratios (HRs) from longitudinal studies that measured 
incident HIV or HCV infection. In studies that found no 
incident cases in the exposed or unexposed group, a 
fraction of a case (0∙5 incident infections) was added to 
both groups before computing the incidence rate ratio. 
We extracted crude and adjusted odds ratios or relative 
risks (RRs) from cross-sectional studies that used 
biological markers (eg, the presence of HCV RNA in the 
absence of HCV antibody) of recent HIV or HCV 
infection. We transformed unadjusted and adjusted odds 
ratios and their 95% CIs to RRs when incidence was 
considered to be common (>10 per 100 person-years) 
using previously published methods.20
We assessed the risk of bias in each study for each 
outcome using the Newcastle–Ottawa Scale,21 in which a 
maximum of nine stars are awarded according to the 
selection of study groups, comparability of the groups, 
and ascertainment of the outcome of interest. The 
Newcastle–Ottawa Scale requires the selection of 
the most important potential confounders that should 
be controlled for in studies. We identified exposure to 
opioid substitution therapy, recent homelessness, and 
stimu lant injecting as important potential confounders 
that should be adjusted for in our analyses. Opioid 
substitution therapy is associated with a reduced risk 
of HCV and HIV acquisition18,19 and with a reduced 
prevalance of incarcer ation.22 Homelessness, and stimu-
lant injecting (although studies generally consider only 
cocaine injecting) are positively associated with risk of 
HCV or HIV acquisition23,24 and incarceration history.13,25 
In assessing the comparability of the groups, one star 
was awarded for adjusting for opioid substitution 
therapy exposure and one star for adjusting for recent 
homelessness, stimulant injecting, or both. Risk of bias 
for unpublished estimates was assessed by referring to 
the study methods in the corresponding published 
paper. For each outcome, publication bias of included 
studies was assessed with a funnel plot and Egger’s 
test.26
To provide a summary estimate for each outcome, 
effect measures and their SEs were log-transformed, 
with unadjusted and adjusted estimates being pooled 
separately. Random effects meta-analysis was used to 
obtain summary effect measures because high between-
study variability was expected. We evaluated between-
study heterogeneity using the I² statistic and the p value 
for heterogeneity (Cochran’s Q statistic).27
Subgroup analyses and random-effects meta-regression 
analyses were done to explore potential sources of 
heterogeneity for outcomes that showed moderate to high 
heterogeneity between studies. All variables significant in 
univariable meta-regression (p≤0∙05) were included 
in multivariable meta-regression; opioid sub- stitution 
therapy coverage and proportion of participants homeless 
at baseline were included a priori in multivariable models. 
Sensitivity analyses were done to assess the effect of 
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including in separate meta-analyses only: studies at low to 
moderate risk of bias (Newcastle–Ottawa Scale≥6), 
longitudinal studies, studies reporting HRs, and studies 
in which more than 90% of study participants were recent 
injectors (injected within past 6 months) at baseline. We 
also assessed the effect of excluding studies in which no 
incident infections were found in one exposure group. We 
did all the analyses using STATA version 14.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
The searches identified 42 809 citations in total, of which 
25 434 were unique records (figure 1). Initial screening of 
titles and abstracts excluded 25 086 records. Following 
the full-text screening of the remaining 348 records, 
seven by use of Google Translate, 40 records were deemed 
as meeting the inclusion criteria. In addition, we 
identified 90 studies of HIV or HCV incidence among 
PWID that met the inclusion criteria but did not report 
the outcomes of interest. The authors of these studies 
and investigators of other cohorts (ten) known to us who 
had not published their incidence data were contacted. 
Of these, unpublished data (40 different effect estimates) 
were obtained from 21 studies; 17 effect estimates were 
obtained from ongoing or completed studies that had not 
yet published their incidence data, 14 from studies with 
publications reporting HIV or HCV incidence but not 
reporting outcomes of interest, and nine were updates of 
previously published effect estimates that included more 
data. From the 62 (41 + 21) studies meeting the inclusion 
criteria, 21 (appendix) were excluded as multiple studies 
Figure 1: Study selection
HCV=hepatitis C virus. PWID=people who inject drugs.
42 809 citations identified by database search
 16 760 from MEDLINE
 21 811 from Embase
                   4238 from PsycINFO
17 375 duplicates excluded
25 434 titles and abstracts screened
25 086 abstracts excluded as not relevant
348 full texts screened for eligibility
308 full-text articles excluded
 49 did not report original results
 12 did not report HCV or HIV
  incidence among PWID
 9 measured HIV/HCV incidence 
  inappropriately (eg self-report)
 238 did not report outcome of interest
100 authors contacted
62 relevant studies with 88 estimates 
21 duplicate data
21 studies with 40 unpublished effect estimates
41 studies included in quantitative synthesis
 14 estimates for recent incarceration
             and HIV
 12 estimates for ever incarceration
             and HIV
     18 estimates for  recent incarceration
             and HCV
     22 estimates for ever incarceration
             and HCV
Study 
period
Location
(city, country)
Study 
design
Sample 
size
Definition of 
recent 
incarceration
Effect of recent 
incarceration
Effect of past 
incarceration
Confounders included in 
adjusted estimates
Aladashvili et al 
(unpublished)
1997–2001 Tbilisi, Batumi, and 
Poti, Georgia
Cohort28,29 1031 Past 12 
months
HIV: IRR 2∙6 (0∙61–11∙18); 
HCV: IRR 1∙56 (0∙57–4∙23)
HIV: IRR 0∙38 (0∙02–6∙23); 
HCV: IRR: 0∙50 (0∙12–2∙01)
∙∙
Azim (unpublished) 2003–07 Dhaka, Bangladesh Cohort30 561 Past 6 months HIV: IRR 0∙64 (0∙15–2∙75); 
HCV: IRR 1∙36 (0∙60–3∙09)
HIV: IRR 1∙44 (0∙42–4∙94); 
HCV: IRR 2∙04 (0∙90–4∙65)
∙∙
Blome et al31 1997–2005 Malmo, Sweden Cohort 332 NA ∙∙ HCV: RR 1∙27 (1∙05–1∙53); 
aRR 1∙3 (1∙06–1∙49)
Intravenous heroin and 
amphetamine use; duration of 
intravenous use of 
amphetamines
Bruneau (unpublished) 1992–2008 Montreal, Canada Cohort32 2137 Past 6 months HIV: HR 1∙88 (1∙34–2∙65); 
aHR 1∙34 (0∙94–1∙89)
HIV: HR 1∙57 (1∙07–2∙29); 
aHR 0∙94 (0∙63, 1∙41)
Age; sex; unstable housing; 
cocaine use; heroin use; syringe 
sharing with people known to 
be HIV positive; repeatedly 
flushing and pulling back 
during injection; sex with 
people known to be HIV 
positive; recruitment period
(Table continues on next page)
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Study 
period
Location
(city, country)
Study 
design
Sample 
size
Definition of 
recent 
incarceration
Effect of recent 
incarceration
Effect of past 
incarceration
Confounders included in 
adjusted estimates
(Continued from previous page)
Bruneau et al33 2004–13 Montreal, Canada Cohort 226 Past 3 months HCV reinfection: HR 0∙94 
(0∙30–3∙10); aHR 0∙95 
(0∙30–3∙30);
∙∙ Method of HCV initial 
clearance; age; gender; cocaine 
injection; heroin injection; 
prescription opioid injection; 
sharing syringe or injection 
paraphernalia
Brunton et al34 1994–96 Auckland, 
New Plymouth, 
Wellington, 
Christchurch, and 
Dunedin, 
New Zealand
Cohort 44 Since last 
follow-up (on 
average 2 years 
apart)
HCV: IRR 2∙75 (0∙34–21∙99) ∙∙ ∙∙
Choopanya et al35 1995–98 Bangkok, Thailand Cohort 1209 Since last visit 
(scheduled for 
every 
3 months)
HIV: IRR 3∙39 (2∙35–4∙90) HIV: IRR 1∙70 (1∙09–2∙65) ∙∙
Craine et al36 2004–06 South Wales, UK Cohort 286 Past 12 
months
HCV: IRR 1∙36 (0∙48–3∙85) ∙∙ ∙∙
Dietze (unpublished) 2008–18 Melbourne, 
Australia
Cohort37 645 NA ∙∙ HCV (primary and 
reinfection): IRR 0∙73 
(0∙47–1∙13)
∙∙
Hagan et al38 2002–05 Baltimore, Seattle, 
New York, 
Los Angeles, and 
Chicago, USA
Cohort 483 NA ∙∙ HCV: IRR 1∙51 (0∙81–2∙8) ∙∙
Havens (unpublished) 2008–11 Kentucky, USA Cohort39 184 Past 6 months HCV: IRR 2∙80 (1∙36–5∙77) HCV: IRR 1∙12 (0∙65–1∙92) ∙∙
Hellard (unpublished) 2005–10 Melbourne, 
Australia
Cohort40 413 NA ∙∙ HCV: HR 0∙52 (0∙14–1∙97) ∙∙
Hope (unpublished) 2011–13 England, Wales, and 
Northern Ireland, UK
Cross-
sectional
2816 NA ∙∙ HCV: OR 1∙16 (0∙82–1∙63); 
aOR 1∙06 (0∙75–1∙51)
Cocaine injection; 
homelessness; prescribed 
treatment for drug use
Hope (unpublished) 2014–15 England, Wales, and 
Northern Ireland, 
UK
Cross-
sectional
1932 NA ∙∙ HCV: OR 1∙74 (0∙93–3∙25); 
aOR 1∙60 (0∙85–3∙03)
Cocaine injection; 
homelessness; prescribed 
treatment for drug use
Hu et al41 1996 Bangkok, Thailand Cross-
sectional
1488 NA ∙∙ HIV: RR 1∙65 (1∙09–2∙51) ∙∙
Hutchinson 
(unpublished)
2008–13 Scotland, UK Cross-
sectional42
4783 Past 6 months HCV: RR 2∙02 (0∙89–4∙61); 
aRR 1∙21 (0∙51-2∙84)
HCV: RR 1∙44 (0∙73–2∙84); 
aRR 1∙22 (0∙61–2∙44)
Homelessness; methadone use; 
injected crack or cocaine in past 
6 months
Iversen (unpublished) 1995–2012 National, Australia Cohort43 3490 Past 12 months HIV: HR 2∙16 (0∙7–6∙65) HIV: HR 0∙71 (0∙24–2∙12) ∙∙
Iversen et al44 1995–2010 National, Australia Cohort 724 Past 12 months HCV: HR 2∙84 (2∙01–4∙02); 
aHR 2∙68 (1∙88–3∙83)
∙∙ Last drug injected; daily 
injection; location; study period
Lucas et al45 2013 15 sites, India Cross-
sectional
14 481 Past 6 months HIV: RR 2∙07 (0∙94–4∙57) ∙∙ ∙∙
Lucidarme et al46 1999–2001 Northern and 
eastern France, 
France
Cohort 165 NA ∙∙ HCV: IRR 1∙91 (0∙71–5∙13) ∙∙
Maher (unpublished) 2012 Australia Cross-
sectional47
2391 Past 12 months HCV: RR 2∙31 (0∙86–6∙21); 
aRR 2∙15 (0∙74–5∙22)
∙∙ Exposure to OST or MMT; 
duration of injecting; cocaine 
use
Martin et al48 2005–12 Bangkok, Thailand Cohort 2413 Past 3 months HIV: HR 3∙10 (1∙70–5∙60); 
aHR 2∙70 (1∙40–4∙90)
∙∙ Age; injection frequency; 
methamphetamine injection; 
shared needles; recently in 
police cell
Mehta (unpublished) 1988–2009 Baltimore, USA Cohort49,50 1983 Past 6 months HIV: IRR 1∙07 (0∙8–1∙42); 
aIRR 0.97 (0∙72-1∙31); 
HCV: IRR 1∙60 (0∙55–4∙68); 
aIRR 2∙39 (0∙78–7∙3)
∙∙ Cocaine injection; heroin 
injection; methadone 
treatment; homelessness
(Table continues on next page)
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Study 
period
Location
(city, country)
Study 
design
Sample 
size
Definition of 
recent 
incarceration
Effect of recent 
incarceration
Effect of past 
incarceration
Confounders included in 
adjusted estimates
(Continued from previous page)
Micallef et al51 1993–2002 Sydney, Australia Cohort 423 NA ∙∙ HCV: IRR 2∙48 (1∙72–3∙59); 
HCV reinfection: IRR 1∙56 
(0∙43–5∙65)
∙∙
Milloy (unpublished) 2005–16 Vancouver, Canada 
(ARYS)
Cohort52 476 Past 6 months HCV: HR 2∙61 (1∙69–4∙04); 
aHR 2∙46 (1∙56–3∙86)
HCV: HR 1∙24 (0∙77–2∙01); 
aHR 1∙28 (0∙77–2∙13)
Methadone treatment; 
homelessness; cocaine injection
Milloy (unpublished) 1996–2016 Vancouver, Canada 
(VIDUS)
Cohort53 1763 Past 6 months HIV: HR 1∙80 (1∙32–2∙44); 
aHR 1∙76 (1∙28–2∙41);
HCV: HR 1∙16 (0∙81–1∙68); 
aHR 1∙12 (0∙77–1∙61)
HIV: HR 0∙82 (0∙58–1∙15); 
aHR 0∙86 (0∙61–1∙21);
HCV: HR 0∙75 (0∙54–1∙05); 
aHR 0∙70 (0∙50–0∙98);
Methadone treatment; 
homelessness; cocaine injection
Morris et al54 2008–11 Sydney, Australia Cohort 294 NA ∙∙ HCV: IRR 0∙33 (0∙09–1∙14) ∙∙
Morris et al54 2004–11 Montreal, Canada Cohort 244 NA ∙∙ HCV: IRR 1∙16 (0∙68–1∙96) ∙∙
Morris et al54 2000–11 San Francisco, USA Cohort 398 NA ∙∙ HCV: IRR 1∙11 (0∙68–1∙83) ∙∙
Mravčík (unpublished) 2002–05 Nine regions, 
Czech Republic
Cohort55 173 NA ∙∙ HCV: IRR 0∙81 (0∙26–2∙5) ∙∙
Platt, Hope and 
Hickman (unpublished)
2006–09 Bristol, Leeds, and 
Birmingham, UK
Cross-
sectional 
56,57
1247 Past 12 
months
HCV: RR 1∙22 (0∙48–3∙09); 
aRR 1∙21 (0∙44–3∙16)
∙∙ OST exposure; homelessness; 
injecting duration; use of 
cocaine
Roy (unpublished) 2003–16 Eastern central 
Canada and Quebec 
and Ontario, 
Canada
Cohort58 1735 Past 6 months HIV: HR 1∙76 (1∙05–2∙96); 
aHR 1∙77 (1∙03–3∙02); 
HCV: HR: 1∙08 (0∙78-1∙49); 
aHR 0∙93 (0∙67-1∙29)
∙∙ Homelessness; OST exposure; 
using syringes used by someone 
else; cocaine most often 
injected drug; injecting daily; 
age; gender; prostitution; urban 
sites
Sacks-Davis et al59 2004–12 Montreal, Canada Cohort 854 Past 3 months HCV: HR 2∙38 (1∙43–3∙95); 
aHR 1∙98 (1∙18–3∙32)
∙∙ Recent cocaine injection; 
recently injected at least daily; 
prescription opioid injection by 
area of residence
Smyrnov 
(unpublished)
2013 29 cities, Ukraine Cross-
sectional60
9502 Past 6 months HIV: OR 1∙91 (0∙26–14∙18) HIV: OR 1∙65 (0∙76–3∙59) ∙∙
Smyth et al61 1992–99 Dublin, Ireland Cohort 100 Since last visit HCV: IRR 0∙79 (0∙42–1∙48) HCV: IRR 1∙73 (1∙03–2∙89) ∙∙
Spittal et al62 2003–09 Vancouver and 
Prince George, 
Canada
Cohort 148 Past 6 months HCV: HR 1∙25 (0∙83–1∙89) HCV: HR 1∙11 (0∙59–2∙09) ∙∙
Strathdee 
(unpublished)
2006–10 Tijuana, Mexico 
(EC3)
Cohort63 1010 Past 6 months HIV: IRR 0∙84 (0∙05–13∙96) HIV: HR 0∙67 (0∙25–1∙85) ∙∙
Strathdee 
(unpublished)
2011–16 Tijuana, Mexico 
(EC4)
Cohort64 737 Past 6 months HIV: HR 0∙67 (0∙28–1∙60) HIV: HR 0∙56 (0∙25–1∙26) ∙∙
Suntharasamai et al65 1999–2003 Bangkok, Thailand Cohort 2546 Past 6 months HIV: HR 2∙00 (1∙40–2∙70); 
aHR 1∙40 (1∙00–1∙90)
∙∙ Injection frequency; sharing 
needles; MMT use
Sypsa et al66 2012–13 Athens, Greece Cohort 3320 NA ∙∙ HIV: HR 2∙4 (1∙27–4∙53); 
aHR 1∙99 (0∙98–3∙85)
Age; gender; country of origin, 
homelessness; size of 
participants’ injecting network; 
OST treatment; main substance 
of use; injecting drug use in past 
month; injecting frequency; 
sharing syringes; use of drugs 
shared between people with a 
used syringe
Tsui et al67 2000–13 San Francisco, USA Cohort 552 Past 3 months HCV: 1∙58 (1∙12–2∙23) ∙∙ ∙∙
Vallejo et al68 2001–06 Barcelona, Madrid, 
and Seville, Spain
Cohort 513 NA ∙∙ HCV: IRR 1∙20 (0∙57–2∙50) ∙∙
Yen (unpublished) 2007–10 Taipei, Taiwan Cohort69 236 NA ∙∙ HIV: IRR 0∙74 (0∙04–14∙4) ∙∙
IRR=incidence rate ratio. HCV=hepatitis C virus. NA=not applicable. RR=relative risk. aRR=adjusted relative risk. HR=hazard ratio. aHR=adjusted hazard ratio. MMT=methadone maintenance treatment. 
aIRR=adjusted incidence rate ratio. OR=odds ratio. aOR=adjusted odds ratio. OST=opioid substitution therapy. ARYS=At Risk Youth Study. VIDUS=Vancouver Infection Drug Users Study. EC3=El Cuete Phase III. 
EC4=El Cuete Phase IV. Unpublished means that the estimates are unpublished.
Table: Study details and outcomes available
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of the same cohort presenting data on the same outcome. 
One study pub lished in non-English was included in the 
review; we obtained the dataset for this study directly and 
so did not depend on Google Translate to obtain the 
effect estimates or baseline characteristics.
The included studies (table) varied in average follow-up 
duration (longitudinal studies only 0∙6–6∙3 years), 
proportion of the sample who were women (0∙0–59∙8%), 
background HIV (0∙0–34∙2%) and HCV (18∙6–82∙0%) 
prevalence, HIV (0∙1–25∙3 per 100 person-years) and 
HCV (0∙5–66 per 100 person-years) incidence, study 
period (1988–2016), and publication year (2000–17).
14 studies, including ten unpublished estimates, re- 
ported the effect of recent incarceration on HIV 
acquisition risk: 12 longitudinal studies and two 
cross-sectional. Definitions of recent incarceration in 
these studies inc luded in the past 3 months, 6 months, or 
12 months, or since last follow-up visit (scheduled for 
every 3 months; appendix). Recent incarceration was 
associated with an 81% increase in HIV acquisition risk 
(RR 1∙81; 95% CI 1∙40–2∙34; p<0∙0001; figure 2) with 
moderate heterogeneity between studies (I²=63∙5%; 
p=0∙001). Pooled effect estimates were higher across 
published studies (2∙59; 1∙91–3∙52; p<0∙0001) than 
across unpublished studies (1∙47; 1∙14–1∙90; p=0∙003; 
figure 2). The effect was reduced in studies that adjusted 
for confounders (1∙48; 1∙16–1∙90; p=0∙002) and in 
studies at low to moderate risk of bias (1∙65; 1∙26–2∙16; 
p=0∙006) but did not differ in other sensitivity analyses 
(appendix).
12 studies, including nine unpublished estimates, 
reported the effect of past incarceration on HIV acqui-
sition risk: ten longitudinal studies and two cross-
sectional. Past incarceration was not significantly 
associated with HIV acquisition risk (RR 1∙25; 95% CI 
0∙94–1∙65; p=0∙112; figure 3) with moderate heterogeneity 
between studies (I²=49∙8%; p=0∙025). Pooled effect 
estimates were higher across published studies (RR 1∙76; 
95% CI 1∙34–2∙32; p<0∙0001) than across unpublished 
studies (RR 1∙00; 0∙73–1∙38; p=0∙980). The effect was 
null among studies that adjusted for confounders 
(RR 1∙06; 0∙71–1∙56; p=0∙785), studies reporting only 
HRs (HR 1∙05; 0∙67–1∙64; p=0∙842), studies at low to 
moderate risk of bias (RR 1∙06; 0∙66–1∙71; p=0∙802), and 
studies in which at least 90% of participants were recent 
injectors at baseline (RR 0∙96, 0∙63–1∙48, p=0∙864; 
appendix).
In the meta-regression (appendix), there was no 
evidence that the effect of past or recent incarceration 
on HIV acquisition risk varied by geographical region 
or country income level. Published estimates of the 
effects of recent incarceration (ratio of RRs 1∙76 [95% CI 
1∙12–2∙76], p=0∙018) and past incarceration (1∙76 
[1∙05–2∙92], p=0∙034) were higher than unpublished 
estimates. The effect of recent in carceration was lower in 
studies involving older partici pants (mean or median age 
≥34∙3 years vs <34∙3 years; ratio of RRs 0∙54 [0∙33–0∙87], 
p=0∙016), and the effect of past incarceration was lower in 
studies with a greater proportion of women (per 10% 
increase in the proportion of women; 0∙78 [0∙64–0∙95], 
p=0∙020) and in studies spanning 4 years or more (vs 
studies spanning <4 years; 0∙56 [0∙35–0∙89], p=0∙019). 
Multivariable meta-regression analyses did not show any 
Figure 2: Meta-analysis of studies showing the crude effect of recent incarceration on the risk of HIV 
acquisition among people who inject drugs, by publication status.
VIDUS=Vancouver Infection Drug Users Study. EC3=El Cuete Phase III. EC4=El Cuete Phase IV.
Published
Lucas et al (2015)45
Choopanya et al (2002)35
Martin et al (2014)48
Suntharasamai et al (2009)65
Subtotal (I2=41·1%, p=0·165)
Unpublished
Iversen (unpublished)43
Azim (unpublished)30
Bruneau (unpublished)32
Milloy (unpublished; VIDUS)53
Roy (unpublished)58
Aladashvili (unpublished)28,29
Strathdee (unpublished; EC3)63
Strathdee (unpublished; EC4)64
Mehta (unpublished)49,50
Smyrnov (unpublished)60
Subtotal (I2=38·5%, p=0·101)
Overall (I2=63·5%, p=0·001)
India
Thailand
Thailand
Thailand
Australia
Bangladesh
Canada
Canada
Canada
Georgia
Mexico
Mexico
USA
Ukraine
Location
2·07 (0·94–4·57)
3·39 (2·35–4·90)
3·10 (1·70–5·60)
2·00 (1·40–2·70)
2·59 (1·91–3·52)
2·16 (0·70–6·65)
0·64 (0·15–2·75)
1·88 (1·34–2·65)
1·80 (1·32–2·44)
1·76 (1·04–2·96)
2·60 (0·61–11·18)
0·84 (0·05–13·96)
0·67 (0·28–1·60)
1·07 (0·80–1·42)
1·91 (0·26–14·18)
1·47 (1·14–1·90)
1·81 (1·40–2·34)
Relative risk (95% CI)
1·00
Figure 3: Meta-analysis of studies showing the crude effect of past incarceration on the risk of HIV acquisition 
among people who inject drugs, by publication status
 VIDUS=Vancouver Infection Drug Users Study. EC3=El Cuete Phase III. EC4=El Cuete Phase IV.
Published
Sypsa et al (2017)66
Choopanya et al (2002)35
Hu et al (2003)41
Subtotal (I2=0·0%, p=0·553)
Unpublished
Iversen (unpublished)43
Azim (unpublished)30
Bruneau (unpublished)32
Milloy (unpublished; VIDUS)53
Aladashvili (unpublished)28,29
Strathdee (unpublished; EC3)63
Strathdee (unpublished; EC4)64
Yen (unpublished)69
Smyrnov (unpublished)60
Subtotal (I2=33·0%, p=0·154)
Overall (I2=49·8%, p=0·025)
Greece
Thailand
Thailand
Australia
Bangladesh
Canada
Canada
Georgia
Mexico
Mexico
Taiwan
Ukraine
2·40 (1·27–4·53)
1·70 (1·09–2·65)
1·58 (1·04–2·41)
1·76 (1·34–2·32)
0·71 (0·24–2·12)
1·44 (0·42–4·94)
1·57 (1·07–2·29)
0·82 (0·58–1·15)
0·38 (0·02–6·23)
0·67 (0·24–1·85)
0·56 (0·25–1·26)
0·74 (0·04–14·40)
1·65 (0·76–3·59)
1·00 (0·73–1·38)
1·25 (0·94–1·65)
1·00
Location Relative risk (95% CI)
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of these associations, but are likely to be underpowered 
(appendix).
18 studies, including ten unpublished estimates, 
reported the effect of recent incarceration on HCV 
acquisition risk: 14 longitudinal studies and three cross-
sectional. Definitions of recent incarceration included in 
the past 3 months, 6 months, or 12 months, or since last 
follow-up visit (on average every 2 years in one study; 
unknown in the other; appendix). Recent incarceration 
was associated with a 62% increase in HCV acquisition 
risk (RR 1∙62; 95% CI 1∙28–2∙05; p<0∙0001; figure 4), 
with moderate heterogeneity between studies (I²=57∙3%; 
p=0∙002). Pooled effect estimates were similar across 
published (RR 1∙58; 95% CI 1∙02–2∙45; p=0∙041) and 
unpublished (1∙61; 1∙22–2∙12; p=0∙001) estimates. The 
effect was the same in studies that adjusted for 
confounders (1∙60; 1∙21–2∙11; p<0∙0009) and did not 
differ in other sensitivity analyses (appendix).
22 studies, including 11 unpublished estimates, 
reported the effect of past incarceration on HCV 
acquisition risk. Past incarceration was associated with a 
21% increase in HCV acquisition risk (RR 1∙21; 95% CI 
1∙02–1∙43; p=0∙027; figure 5), with moderate hetero-
geneity between studies (I²=50∙6%; p=0∙004). Pooled 
effect estimates were higher in published studies (1∙39; 
1∙11–1∙74; p=0∙004) than in unpublished studies (1∙05; 
0∙84–1∙30; p=0∙680). In sensitivity analyses (appendix), 
the effect was not significant in studies that adjusted for 
confounders (1∙12; 0∙88–1∙42; p=0∙366), in those that 
had low to moderate risk of bias (0∙96; 0∙75–1∙22; 
p=0∙724), in those that reported only HRs (HR 0∙92; 
95% CI 0∙68–1·25; p=0∙595), and in those in which at 
least 90% of participants were recent injectors at baseline 
(RR 1∙03; 95% CI 0∙80–1∙32; p=0∙824).
In the univariable meta-regression, there was no 
evidence that the effect of past or recent incarceration on 
HCV acquisition risk varied by geographical region, 
country income level, or proportion of female participants 
(appendix). There was a greater effect for recent 
incarceration in countries with higher prevalences of 
incar ceration (greater than or equal to the global average 
[144 per 100 000 population] or higher vs less than global 
average; ratio RRs 1∙74 [95% CI 1∙09–2∙76], p=0∙022; 
appendix). The effect of past incarceration was lower in 
more recent studies (midpoint of study October, 2005 or 
later vs earlier than October, 2005; ratio of RRs 
0∙69 [0∙50–0∙95], p=0∙024; appendix). Multivariable 
meta-regression analyses did not show any of these asso-
ciations, but are likely to be under powered (appendix).
In univariable meta-regression (appendix) of the 
adjusted estimates of the effect of recent incarceration 
on HCV acquisition risk, there was no evidence that 
estimates adjusted for recent homelessness (ratio of 
RRs 0∙66 [95% CI 0∙37–1∙17], p=0∙132), or opioid 
substitution therapy exposure (0∙68 [0∙37–1∙26], 
p=0∙192), or recent stimulant injecting (0.90 [0∙37–2∙20], 
p=0∙795) were lower than those not adjusting for these 
variables (appendix).
Visual inspection of the funnel plots (appendix) and 
Egger’s tests (p≥0∙507) found no evidence of publication 
bias. For the 66 estimates included in the meta-analyses, 
the most common rating on the Newcastle–Ottawa Scale 
was six (n=19) or seven (n=15) stars out of a possible 
nine, signifying a moderate risk of bias (higher ratings 
represent a lower risk of bias; appendix). The ratings 
varied from three (n=1) to nine (n=7) stars. The average 
rating did not vary across outcomes.
Discussion
We found strong evidence that recent incarceration is 
associated with increased HIV and HCV acquisition risk 
among PWID. Recent incarceration was associated with 
an 81% and 62% increased risk of HIV and HCV 
acquisition, respectively. Past incarceration was only 
weakly associated with an increase in HCV acquisition 
risk and was not associated with an increase in HIV 
acquisition risk; the association with HCV acquisition 
was removed in adjusted analyses.
There was evidence that the effect of recent incar-
ceration on HCV acquisition risk was greater in studies 
from countries with higher prevalences of incarceration 
and that the effect of recent incarceration on HIV 
acquisition risk was lower in studies with older 
participants. There was also evidence that the effects of 
recent incarceration on HCV acquisition risk were lower 
Figure 4: Meta-analysis of studies showing the crude effect of recent incarceration on the risk of hepatitis C 
virus acquisition among people who inject drugs, by publication status
 ARYS=At Risk Youth Study. VIDUS=Vancouver Infection Drug Users Study.
Published
Iversen et al (2013)44
Bruneau et al (2015)33
Sacks−Davis et al (2016)59
Spittal et al (2012)62
Smyth et al (2003)61
Brunton et al (2000)34
Craine et al (2009)36
Subtotal  (I2=68·4%, p=0·004)
Unpublished
Maher (unpublished)47
Azim (unpublished)30
Milloy (unpublished; ARYS)52
Milloy (unpublished; VIDUS)53
Roy (unpublished)58
Aladashvili (unpublished)28,29
Havens (unpublished)39
Mehta (unpublished)49,50
Hutchinson (unpublished)42
Platt et al (unpublished)56,57
Subtotal  (I2=45·6%, p=0·057)
Overall  (I2=57·3%, p=0·002)
Australia
Canada
Canada
Canada
Ireland
New Zealand
UK
Australia
Bangladesh
Canada
Canada
Canada
Georgia
USA
USA
UK
UK
2·84 (2·01–4·02)
0·94 (0·30–3·10)
2·38 (1·43–3·95)
1·25 (0·83–1·89)
0·79 (0·42–1·48)
2·75 (0·34–21·99)
1·36 (0·48–3·85)
1·58 (1·02–2·45)
2·31 (0·86–6·21)
1·36 (0·60–3·09)
2·61 (1·69–4·04)
1·16 (0·81–1·68)
1·08 (0·78–1·49)
1·56 (0·57–4·23)
2·80 (1·36–5·77)
1·60 (0·55–4·68)
2·02 (0·89–4·61)
1·22 (0·48–3·09)
1·61 (1·22–2·12)
1·62 (1·28–2·05)
1·00
Location Relative risk (95% CI)
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if adjusted for recent homelessness or exposure to opioid 
substitution therapy, although these results were not 
significant.
Our study strengthens previously published evidence 
through contacting a large number of authors of 
incidence studies with unpublished estimates, thereby 
minimising publication bias. Nonetheless, our study has 
several limitations.
Although the search was not limited by language or 
publication source, little data came from the countries 
with the largest populations of PWID.5 Furthermore, 
most included studies were from high-income countries 
(34 of 48), with no studies being included from low-
income countries or the Middle East and Africa. Whereas 
we found moderate to high amounts of heterogeneity 
between studies, there was no evidence that this was 
explained by geographical region or country income 
level.
It is possible that the effect of past incarceration on 
HCV acquisition risk could partly be attributable to 
higher-risk PWID being more likely to be incarcerated. 
Similarly, some of the increased risk associated with 
recent incarceration could repre sent increased acquisition 
risk during or even before incarceration, rather than 
following release. The limited availability of data on HIV 
and HCV incidence among incarcerated PWID17 
prevented any systematic com parisons between settings 
with low or high incidence in prisons. Importantly, 
however, when pooling estimates from Scotland and 
Australia, settings which both have documented low 
HCV incidence among incarcerated PWID,70,71 we found 
evidence of a strong effect of recent incarceration on 
HCV acquisition risk (appendix), suggesting increased 
risk after release. Additionally, there is evidence from 
Australia for lower HCV incidence in continuously 
incarcerated PWID than among PWID that are released 
and re-incarcerated,71 also suggesting heightened risk 
associated with release.
Data on incarceration were scarce in the studies and so 
we were unable to consider whether the effect of 
incarceration history differed by type of incarceration, 
duration of most recent sentence, whether opioid 
substitution therapy was given in prison, or overall 
frequency or length of incarceration. Future studies 
should include further detail on these factors.
It is probable that our multivariable, meta-regression 
analyses, which were prespecified in our protocol, 
suffered from a lack of power owing to the number of 
studies included in the review. As such, the findings of 
these analyses should be interpreted with care—
specifically, a lack of evidence for an association does not 
mean that there is a lack of an association. It is important 
that future studies are designed to investigate how 
incarceration elevates HIV and HCV acquisition risk and 
what influences the magnitude of this increased risk.
All of the studies included in this meta-analysis were 
observational in nature, with many having a high risk of 
bias and few adjusting their effect estimates for potential 
confounders. Importantly, there were still strong 
associations between recent incarceration and increased 
HCV and HIV acquisition risk when limiting the analysis 
to adjusted estimates, or to studies at low to medium risk 
of bias.
Other studies have synthesised available evidence for 
the effect of interventions on HIV or HCV acquisition risk 
among PWID,19,72,73 considered the effect of polydrug use 
on HIV acquisition risk,23 and assessed the effect of laws 
criminalising drug use on HIV prevention and treatment 
outcomes among PWID.12 To our knowledge, however, 
this study is the first to have quantitatively synthesised 
available evidence on the effect of incar ceration on HIV or 
HCV acquisition risk among PWID. Our findings are 
consistent with studies that find incarceration is associated 
with relapse to injecting drug use8 and that recently 
incarcerated PWID exhibit increased injecting risk 
behaviour10,11 and reduced access to harm reduction 
interventions14 compared with PWID who do not report 
recent incarceration. Our findings are also consistent with 
studies that indicate increased risk of drug-related 
Figure 5: Meta-analysis of studies showing the crude effect of past incarceration on the risk of hepatitis C 
virus acquisition among people who inject drugs, by publication status 
ARYS=At Risk Youth Study. VIDUS=Vancouver Infection Drug Users Study.  UAM=Unlinked Anonymous Monitoring 
survey of people who inject drugs.
Published
Micallef et al (2007)51 (re-infection)
Micallef et al (2007)51 (primary)
Morris et al (2017)54
Morris et al (2017)54
Spittal et al (2012)62
Lucidarme et al (2004)46
Smyth et al (2003)61
Vallejo et al (2015)68
Blome et al (2011)31
Hagan et al (2010)38
Morris et al (2017)54
Subtotal  (I2=46·3%, p=0·046)
Unpublished
Dietze (unpublished)37
Hellard (unpublished)40
Azim (unpublished)30
Milloy (unpublished; ARYS)52
Milloy (unpublished; VIDUS)53
Mravčík (unpublished)55
Aladashvili (unpublished)28,29
Havens (unpublished)39
Hope (unpublished; UAM 2011–13)
Hope (unpublished; UAM 2014–15)
Hutchinson (unpublished)42
Subtotal  (I2=35·5%, p=0·115)
Overall  (I2=50·6%, p=0·004)
Australia
Australia
Australia
Canada
Canada
France
Ireland
Spain
Sweden
USA
USA
Australia
Australia
Bangladesh
Canada
Canada
Czech Republic
Georgia
USA
UK
UK
UK
1·56 (0·43–5·65)
2·48 (1·72–3·59)
0·33 (0·09–1·14)
1·16 (0·68–1·96)
1·11 (0·59–2·09)
1·91 (0·71–5·13)
1·73 (1·03–2·89)
1·20 (0·57–2·50)
1·27 (1·05–1·53)
1·51 (0·81–2·80)
1·11 (0·68–1·83)
1·39 (1·11–1·74)
0·73 (0·47–1·13)
0·52 (0·14–1·97)
2·04 (0·90–4·65)
1·24 (0·77–2·01)
0·75 (0·54–1·05)
0·81 (0·26–2·50)
0·50 (0·12–2·01)
1·12 (0·65–1·92)
1·15 (0·83–1·60)
1·74 (0·92–3·25)
1·44 (0·73–2·84)
1·05 (0·84–1·30)
1·21 (1·02–1·43)
Location Relative risk (95% CI)
1·00
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mortality following release.9 Whereas a reduction in 
opioid tolerance during incarceration is a probable 
explanation for this, evidence that elevated risk of mortality 
can persist for a year after release74 also suggests a 
sustained period of unstable drug use following release.
Our findings suggest that incarceration is an important 
enhancer of HIV and HCV acquisition risk among PWID 
globally. The mechanisms through which this occurs are 
also likely to affect PWID who are already infected with 
HIV or HCV, further increasing the contribution of 
incarceration to elevating HIV and HCV transmission. 
Mathematical modelling considering these effects 
suggests that incarceration could be an important driver 
of HIV and HCV transmission among PWID in many 
settings.11,15–17 Additionally, our analysis suggests that the 
effects of incarceration might be greater in countries 
with high prevalences of incarceration, providing further 
impetus for reducing the incarceration of PWID.
Both opioid substitution therapy and needle and syringe 
programmes have been shown to be effective at reducing 
HCV and HIV transmission among PWID in the 
community.19,72,73 Although evidence of the effectiveness of 
opioid substitution therapy and needle and syringe 
programmes at reducing HIV and HCV transmission 
among PWID in prisons is scare, there is evidence that 
prison-based opioid substitution therapy is associated 
with reduced injecting risk and increased treatment entry 
and retention following release,75 and that prison-based 
needle and syringe programmes are effective at reducing 
syringe sharing among PWID and do not encourage drug 
use or represent a threat to safety.76 It is therefore probable 
that prison-based harm reduction interventions, with 
effective linkage to services following release, could 
reduce the risk associated with incarceration, as suggested 
by recent modelling.11,17 Despite this, most countries do 
not provide opioid substitution therapy and needle and 
syringe programmes within prisons.77
However, these interventions are unlikely to be 
sufficient to fully prevent the elevated risk associated with 
incarceration and the period after release. Incarceration 
is interlinked with many other social determinants of 
health, including poverty, unemploy ment, and home- 
lessness, and so it is probable that addressing these 
factors will be important for reducing the elevated 
acquisition risk associated with recent incarceration. We 
found that the effects of recent incarceration on HCV 
acquisition risk were lower when estimates were adjusted 
for recent homelessness, although these results were not 
significant.  Homelessness following release could be on 
the causal pathway or act in synergy with incarceration to 
further elevate HCV acquisition risk; thus, the provision 
of stable housing following release could reduce the 
effects of recent incar ceration on acquisition risk. Further 
research is required to better elucidate the factors 
associated with incarceration that increase HIV and HCV 
acquisition risk, aiding the development of interventions 
to reduce these risks.
In conclusion, our study provides strong evidence that 
recent incarceration is associated with substantial 
increases in HIV and HCV acquisition risk among 
PWID. Owing to the high prevalences of incarceration 
among PWID, incarceration is likely to be an important 
driver of HCV and HIV transmission and transmission 
among PWID. Our findings add to the growing body of 
evidence for the harms associated with international 
drug policy, which result in many people who use 
drugs being incarcerated, and support calls for 
decriminalisation of illicit drug use and greater access to 
prison-based harm reduction, with linkage following 
release. However, it is likely that addressing many of the 
multiple social vulnerabilities experienced by PWID will 
also be required to fully reduce the risks associated with 
incarceration.
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